CTCBIO Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
March 21, 2024 at 05:17 am EDT
Share
CTCBIO Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was KRW 0.00021 million compared to negative sales of KRW 0.00029 million a year ago. Net loss was KRW 15,587.9 million compared to net income of KRW 4,703.8 million a year ago.
Basic loss per share from continuing operations was KRW 652 compared to basic earnings per share from continuing operations of KRW 197 a year ago. Diluted loss per share from continuing operations was KRW 652 compared to diluted earnings per share from continuing operations of KRW 197 a year ago. Basic loss per share was KRW 652 compared to basic earnings per share of KRW 197 a year ago.
CTCBIO Inc. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals, veterinary drugs, animal feed supplements and functional foods. It pharmaceuticals include anticancer agents, antibiotics, bone injury treatments, antiulcer agents, blood flow stimulants and others. Its veterinary drugs include vaccines, antibiotics, immune enhancers, enzymes, organic acid, avian influenza-related agents and others. Its animal feed supplements include pigments, kapok seed meal, sesame meal and others. Its functional food business includes the development and manufacture of enzymes, lactobacillus and related products mainly used in dairy products. It also involves in the development of pharmaceutical manufacturing technology and know-how. The Company distributes its products within domestic market and to overseas markets.
CTCBIO INC. 
